• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)

    12/10/21 5:24:12 PM ET
    $ODT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ODT alert in real time by email
    SC 13G/A 1 odonate13gamd2.htm

    0UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    Odonate Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    676079106

    (CUSIP Number)

    December 10, 2021

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    1

    CUSIP NO. 676079106

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) OO, IA

    2

    CUSIP NO. 676079106

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

    3

    CUSIP NO. 676079106

     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

    4

    CUSIP NO. 676079106

     

    Item1.
    (a)Name of Issuer

    Odonate Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    3 East 28th Street, 10th Floor, New York, New York 10016

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.01 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 676079106.
    5

    CUSIP NO. 676079106

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The funds managed by EcoR1, including Qualified Fund, hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: December 10, 2021

     

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman, Manager

     

     
    6

    CUSIP NO. 676079106

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: December 10, 2021

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman, Manager

     

     

     

    Get the next $ODT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ODT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ODT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Odonate Announces Expected Delisting of Its Stock

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The

      1/7/22 9:00:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou

      11/17/21 7:45:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Odonate Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously

      3/22/21 12:46:40 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics downgraded by Cowen

      Cowen downgraded Odonate Therapeutics from Outperform to Market Perform

      3/22/21 11:27:45 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Odonate Therapeutics Inc.

      25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)

      1/25/22 5:30:50 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      1/7/22 9:00:35 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      11/18/21 5:00:34 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ODT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ODT
    Financials

    Live finance-specific insights

    See more
    • SEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      12/10/21 6:50:07 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/24/21 6:00:33 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/19/21 7:22:38 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      12/10/21 5:24:12 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/26/21 5:01:04 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/22/21 11:08:29 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en

      7/27/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en

      5/14/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care